Sentaro Kusuhara

Dr. Sentaro Kusuhara

Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SKSentaro Kusuhara
Sentaro Kusuhara
MEMichael F. Teraoka Escaño
Michael F. Teraoka Escaño
SFShigeki Fujii
Shigeki Fujii
YNYoriko Nakanishi
Yoriko Nakanishi
YTYasushi Tamura
Yasushi Tamura
ANAkira Negi
Akira Negi

9 February 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
SOShuntaro Ogura
Shuntaro Ogura
KKKaori Kurata
Kaori Kurata
YHYuki Hattori
Yuki Hattori
HTHiroshi Takase
Hiroshi Takase
TIToshina Ishiguro-Oonuma
Toshina Ishiguro-Oonuma
AUAkiyoshi Uemura
Akiyoshi Uemura
In the central nervous system, endothelial cells (ECs) and pericytes (PCs) of blood vessel walls cooperatively form a physical and chemical barrier to maintain neural homeostasis. However, in diabetic retinopathy (DR), the loss of PCs from vessel walls is assumed to cause breakdown of the blood-retina barrier (BRB) and subsequent vision-threatening vascular dysfunctions. Nonetheless, the lack of adequate DR animal models has precluded disease understanding and drug discovery. Here, by using an anti-PDGFRβ antibody, we show that transient inhibition of the PC recruitment to developing retinal vessels sustained EC-PC dissociations and BRB breakdown in adult mouse retinas, reproducing characteristic features of DR such as hyperpermeability, hypoperfusion, and neoangiogenesis. Notably, PC depletion directly induced inflammatory responses in ECs and perivascular infiltration of macrophages, whereby macrophage-derived VEGF and placental growth factor (PlGF) activated VEGFR1 in macrophages and VEGFR2 in ECs. Moreover, angiopoietin-2 (Angpt2) upregulation and Tie1 downregulation activated FOXO1 in PC-free ECs locally at the leaky aneurysms. This cycle of vessel damage was shut down by simultaneously blocking VEGF, PlGF, and Angpt2, thus restoring the BRB integrity. Together, our model provides new opportunities for identifying the sequential events triggered by PC deficiency, not only in DR, but also in various neurological disorders.

1 December 2004 in Ophthalmology
Verified
Journal Article
Closed access
AKAkiyasu Kanamori
Akiyasu Kanamori
MNMakoto Nakamura
Makoto Nakamura
NMNoriko Matsui
Noriko Matsui
ANAzusa Nagai
Azusa Nagai
YNYoriko Nakanishi
Yoriko Nakanishi
ANAkira Negi
Akira Negi

21 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSentaro Kusuhara
Sentaro Kusuhara
YFYoko Fukushima
Yoko Fukushima
SFShigetomo Fukuhara
Shigetomo Fukuhara
LJLars Martin Jakt
Lars Martin Jakt
MOMitsuhiro Okada
Mitsuhiro Okada
AUAkiyoshi Uemura
Akiyoshi Uemura
Drugs inhibiting vascular endothelial growth factor (VEGF) signaling are globally administered to suppress deregulated angiogenesis in a variety of eye diseases. However, anti-VEGF therapy potentially affects the normal functions of retinal neurons and glias which constitutively express VEGF receptor 2. Thus, it is desirable to identify novel drug targets which are exclusively expressed in endothelial cells (ECs). Here we attempted to identify an EC-specific Rho guanine nucleotide exchange factor (GEF) and evaluate its role in retinal angiogenesis. By exploiting fluorescence-activated cell sorting and microarray analyses in conjunction with in silico bioinformatics analyses, we comprehensively identified endothelial genes in angiogenic retinal vessels of postnatal mice. Of 9 RhoGEFs which were highly expressed in retinal ECs, we show that Arhgef15 acted as an EC-specific GEF to mediate VEGF-induced Cdc42 activation and potentiated RhoJ inactivation, thereby promoting actin polymerization and cell motility. Disruption of the Arhgef15 gene led to delayed extension of vascular networks and subsequent reduction of total vessel areas in postnatal mouse retinas. Our study provides information useful to the development of new means of selectively manipulating angiogenesis without affecting homeostasis in un-targeted tissues; not only in eyes but also in various disease settings such as cancer.

6 August 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMaya Kishi
Maya Kishi
AMAkiko Miki
Akiko Miki
AKAya Kamimura
Aya Kamimura
MOMina Okuda
Mina Okuda
WMWataru Matsumiya
Wataru Matsumiya
MNMakoto Nakamura
Makoto Nakamura
To evaluate the functional and anatomical effects of switching to faricimab for patients with neovascular age-related macular degeneration (nAMD) refractory to intravitreal aflibercept, this retrospective study evaluated patients with nAMD who received intravitreal injections of aflibercept (IVA) every <8 weeks and were switched to faricimab. After switching, the patients were treated with a treatment and extended regimen that started with the interval just before switching and received at least three injections. We evaluated changes in the best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), treatment interval, and presence of retinal fluid. Overall, 55 eyes from 55 patients were examined. After three injections of faricimab, the BCVA and CCT did not change significantly. However, the CRT decreased significantly (p < 0.05), the injection interval was significantly extended (7.5 ± 2.3 vs. 5.9 ± 1.5 weeks, p < 0.01), and the rates of the presence of intraretinal fluid and subretinal fluid decreased significantly to 16.4% and 40% of eyes, respectively (both p < 0.01). An ocular adverse event (retinal pigment epithelium tear) developed in one eye. Switching to faricimab was effective for anatomic changes. It may be an additional treatment option for some eyes refractory to IVA.

26 November 2013 in Ophthalmologica
Verified
Journal Article
Open access
PDF file
SKSentaro Kusuhara
Sentaro Kusuhara
ANAkira Negi
Akira Negi
Since Kelly and Wendel [Arch Ophthalmol 1991;109:654-659] first reported successfully treating macular holes (MHs) using pars plana vitrectomy in 1991, MH surgery has been constantly improved. For example, introducing the removal of the internal limiting membrane considerably increased the closure rate of MHs, and the advent of microincision vitrectomy surgery reduced surgical trauma and decreased patient discomfort after surgery. As modern MH surgery can achieve a higher anatomical success rate and alleviate patients' postoperative distress, postoperative visual outcomes have lately become the primary concern. Informing patients of the expected visual acuity and visual improvement before surgery is ideal, but predicting postoperative visual outcomes is difficult because a large number of factors are associated with them. In this paper, we review previous studies and provide accumulating evidence for the relationship between individual prognostic factors and visual outcomes after MH surgery.